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Abstract
MicroRNAs (miRNAs) are key regulators of gene expression and contribute to a variety of biological processes. Abnormal
miRNA expression has been reported in various diseases including pathophysiology of breast cancer, where they regulate
protumorigenic processes including vascular invasiveness, estrogen receptor status, chemotherapy resistance, invasion and
metastasis. The miRBase sequence database, a public repository for newly discovered miRNAs, has grown rapidly with
approximately .10,000 entries to date. Despite this rapid growth, many miRNAs have not yet been validated, and several
others are yet to be identified. A lack of a full complement of miRNAs has imposed limitations on recognizing their
important roles in cancer, including breast cancer. Using deep sequencing technology, we have identified 189 candidate
novel microRNAs in human breast cancer cell lines with diverse tumorigenic potential. We further show that analysis of 500-
nucleotide pri-microRNA secondary structure constitutes a reliable method to predict bona fide miRNAs as judged by
experimental validation. Candidate novel breast cancer miRNAs with stem lengths of greater than 30 bp resulted in the
generation of precursor and mature sequences in vivo. On the other hand, candidates with stem length less than 30 bp
were less efficient in producing mature miRNA. This approach may be used to predict which candidate novel miRNA would
qualify as bona fide miRNAs from deep sequencing data with approximately 90% accuracy.
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Introduction
MicroRNAs (miRNAs) are small, non-coding RNAs (18,23
nucleotide in size) that regulate gene expression by sequence specific
binding to messenger RNA (mRNA), triggering either translation
repression or RNA degradation [1]. miRNAs play important roles
in various biological processes including cell growth, differentiation,
and development [2,3]. Abnormal miRNA expression has been
reported in various diseases including cancer [4,5,6,7], and are
therefore considered to be promising diagnostic and therapeutic
candidates for the treatment of human disease. miRNAs are
transcribed as large primary microRNAs (pri-miRNAs, varying in
length from a few hundred bases up to tens of kilobases) [8], which
are further trimmed into precursor microRNAs (pre-miRNAs
,75 nt) by the enzyme Drosha in the nucleus. The pre-miRNAs
are exported to the cytoplasm where they are processed into mature
miRNAs (,22 nt) by the enzyme Dicer. Based on the thermody-
namic stability of each end of this duplex, one of the strands is
believed to be preferentially incorporated into the RNA-induced
silencing complex (RISC), producing a biologically active miRNA
and an inactive miRNA star sequence [9].
Currently, 1100 mature miRNAs have been discovered in
mammalian systems and deposited in the publicly available
miRNA database miRBase (Release 16; http://microrna.sanger.
ac.uk/) [10,11]. Although computational algorithms have predict-
ed over 1500 human miRNAs [12], little over 1000 miRNAs
(1100 in miRBase v16.0) have been assigned and validated in the
human genome [11,13]. Thus many miRNAs that occur in a cell
have remained invalidated, and several others have not even been
identified. A greater understanding of the roles of individual
miRNAs requires comprehensive analysis of the full complement
of such molecules and their relative abundance.
Recently, development of next generation sequencing technol-
ogies has revolutionized miRNA profiling in various model
systems [14,15,16,17]. Deep sequencing of miRNAs provides a
highly quantitative estimate of known individual miRNA species,
and has the potential for discovering novel miRNAs, even those
that occur at low frequencies [18,19]. Given that miRNAs
contribute significantly to the pathophysiology of breast cancer
by contributing to invasion and metastasis [20,21,22,23], epithelial
to mesenchymal transition [24,25], and maintenance of breast
stem cells [26], we have used a deep sequencing approach to
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identify novel miRNAs in human breast cancer cell lines that
exhibit diverse tumorigenic potential. Multiple criteria, including
frequencies of individual sequence reads, secondary structure of
hairpins, thermodynamic stability, and the presence of star
sequences were used to predict 189 novel miRNAs. We further
developed a computational method based on the analysis of stem
lengths in 500-nt pri-microRNA secondary structures to predict
which candidate miRNA would qualify as bona fide miRNAs.
Notably, accurate prediction was observed in 90% of the cases as
judged by experimental validation.
Results and Discussion
Deep sequencing uncovers miRNAs in breast cancer cells
Total RNA isolated from human breast cell lines MCF10A
(transformed primary breast epithelial cell, nontumorigenic),
MCF7 (tumorigenic, nonmetastatic) and MDA-MB-231 (tumori-
genic, metastatic) was size fractionated (15 to 32bp in length) and
used to generate libraries for sequencing with the Illumina Solexa
deep sequencing platform (Illumina 16 genome sequencer,
Solexa). Approximately 4–5 million sequence reads obtained from
each breast cancer cell line were subjected to quality control
analysis to remove low quality sequences, and the remaining high
confidence reads were used for identifying miRNAs as described in
Methods. Next, the sequence reads were aligned to known
miRNAs sequences in the miRNA database (miRBase v16) as
shown in the schematic (Fig. 1a). Approximately 82% of the reads
matched with the known human miRNAs, indicating that
miRNAs had been successfully sequenced (Supplementary
Table S1). These reads were eliminated from the data sets, and
the remaining unmatched sequences (approx 0.5 million reads)
were used for identifying novel miRNAs. Size distribution analysis
showed that both the matched and unmatched categories
predominantly consisted of reads approximately 22–23 nt in
length (Fig. 1b). To identify novel miRNA, we considered
sequence reads with a frequency $2, and approximately 0.2
million reads qualified this criteria.
Identification of candidate novel miRNAs
To predict potentially novel miRNAs, we first combined all of
the unmatched sequence reads from individual breast cancer cell
lines and collapsed them to obtain a set of unique sequences. The
reads were analyzed by miRDeep algorithm [18], which utilizes a
probabilistic model of miRNA biogenesis to score compatibility of
the position and frequency of sequenced RNA with the secondary
structure of the miRNA precursor. Briefly, the reads were aligned
to the genome database (human genome v18, UCSC genome
browser) using the Megablast program [27]. Only sequences that
aligned to the human genome were used for extracting ,75bp
potential pre-miRNA sequences. The ,75bp pre-miRNA se-
quences were tested for their ability to form a characteristic
hairpin structure using the Vienna RNA fold package v1.8 [28].
Sequences that formed reliable hairpin structures were further
analyzed to determine features such as thermodynamics stability,
presence of star sequences, and phylogenetic conservation [18].
Using a cut-off log-odds score of 1.0 (that is, results that are 10-fold
more likely than random sequence to match the form of a
predicted microRNA precursor, according to the miRDeep
algorithm), we obtained a total of 189 potential novel miRNAs,
which have the highest probability of being bona fide novel
miRNAs (Supplementary Table S2). Of the 189 potential
novel miRNAs, 30 candidates showed frequencies of .50 in both
MCF10A, MCF7 or MDA-MB-231 breast cells (Table 1) and 27
candidate miRNAs contained the presence of star sequences. 7
candidate miRNAs had sequence homologies to known human
miRNAs (1–2bp mismatch), and were located on different
chromosome loci. 4 candidates matched with miRNAs of other
species (1–2 bp mismatch), but did not match to human miRNAs.
Table 2 depicts the top 30 candidate miRNAs ranked on the basis
of read frequencies.
Experimental validation of candidate novel miRNAs
To determine which of these predicted candidates were bona
fide miRNAs, a subset of the novel miRNA candidates from top 30
candidate miRNAs (Table 2) were subjected to experimental
validation. It is important to note that, in principle, a miRNA is
considered validated when expression of its ,75-nt precursor and
,22-nt mature processed fragment can be demonstrated [29]. In
this context, two candidate miRNAs miR-B6 and miR-B7
depicted in Table 2 with comparable frequencies and high
similarity with known miRNAs were first selected for northern blot
analysis of total RNA. hsa-miR-21, a highly abundant known
miRNA in our deep sequencing data was used as a control.
Surprisingly, we observed that only miR-B6 showed both the
precursor and mature processed fragment in northern blot analysis
(Fig. 2A), even though both candidate miRNAs had qualified
miRDeep parameters including presence of typical fold-back
hairpin structures. There is a distinct possibility that the
suboptimal sensitivity of northern blotting may be the cause for
our failure to detect endogenous mature miRNAs. To discount
this possibility, we cloned the 500bp of miR-B7 precursor
sequence (with GFP) in a lentiviral vector and generated 293T
cells stably expressing the miR-B7 precursor. Again, overexpres-
sion of mir-B7 did not reveal either the pre-miRNA or the mature
mir-B7 product consistent with previous results (Fig. 2A).
The stem-loop hairpin structure is a valuable, but not
discriminative, characteristic of pre-miRNAs, because previous
studies have shown that folding free energy and structural criteria
often used to generate miRNA precursors are not the most
informative when it comes to distinguishing precursors from other
non-miRNA conserved hairpins [30]. Therefore, to determine the
possible cause for the failure of miR-B7 to generate a mature
sequence, we examined its RNA secondary structure by generating
fold-back hairpin structure derived from a standard ,75-nt
precursor sequence or from a larger ,500-nt precursor as
depicted for known miRNA miR-21 (Supplementary Fig.
S1). Notably, while the ,75-nt precursor sequence generated a
characteristic miRNA stem-loop structure, the 500-nt precursor
sequence yielded a distorted stem-loop structure (Fig. 2C), as
determined by the reduction in the length of the stable stem. In
contrast, both the ,75-nt and the ,500-nt precursor for miR-B6
generated a robust stem-loop structure with an intact stem
(Fig. 2B). This observation led to the hypothesis that the analysis
of the stem-loop structure obtained from a 500-nt precursor may
be an important determinant for evaluating whether a mature
miRNA will be generated in vivo from precursor sequences. To test
this hypothesis, we generated a positive sample dataset by selecting
the 100 most highly expressed miRNAs, including miR-21, from
our deep sequencing data that matched known miRNAs in the
miRBase. These reads were aligned to the genome database
(human genome v18, UCSC genome browser) using the Mega-
blast program [27]. Next, for each miRNA, we extracted ,500-nt
pri-miRNA sequences, generated secondary structures and
measured the length of stem containing mature miRNA sequence
(length between hairpin loop junction and bulge defined as more
than four consecutive non-paring nucleotides or starting point of
other branch of stems). The results showed that a majority (.90%)
of highly expressed known miRNAs in our positive sample dataset
Novel Breast miRNAs from Pri-miRNA Structures
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Table 1. Characterization of 189 candidate miRNAs.
Category Frequency
High confidence candidate miRNAs which has high frequency reads (.50) 30
Highly similar to known human miRNA (1,2 mismatched) but located on different chromosome 7
No match with human miRNAs but highly similar to other species (0,2 mismatched) 4
Presence of star sequence 27
Remaining 137
doi:10.1371/journal.pone.0016403.t001
Figure 1. Analysis of deep sequencing data to identify novel miRNA. (A) Flowchart depicting analysis pipeline. Numbers of sequencing reads
at each step of the analysis are shown in parentheses. (B) Size distribution (bp) shown for sequence reads that matched known miRNAs (matched
reads) in miRBase and reads that did not match (non-matched reads) for human breast cell lines MCF10A, MCF7 and MDA-231 cells.
doi:10.1371/journal.pone.0016403.g001
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consisted of stem lengths more than 30bp in length and only 7.5%
had stem lengths of less than 30 bp (Fig. 3A). Using this information
from the training set, we performed identical analysis on 189-
candidate novel miRNAs identified by miRDeep (top 30 candidate
miRNAs listed in Supplementary Fig. S2). Interestingly, the
frequency of the length of stem showed a typical normal distribution
pattern with stem lengths ranging from 0–70bp and 41.5%
constituting stem lengths less than 30 bp (Fig. 3B). Based on the
data from the training set, we inferred that novel candidate miRNAs
with stem lengths of $30bp may comprise bona fide miRNAs. To
test this hypothesis, we selected the top 20 most highly expressed
candidate miRNAs with sequence homologies with other species
and performed northern blot analysis on either total RNAs
harvested from breast cancer cells or RNA extracted following
expression of precursors cloned in plasmids to detect processed 70-
nt precursor and a mature 22-nt miRNA. The results summarized
in Supplementary Table S3 shows that candidate miRNAs with
longer stem lengths (cutoff $30, Group B in Fig. 4) resulted in the
generation of precursor and mature sequences (4 out of 5). On the
other hand, candidates with short stem length (cutoff,30, Group A
in Fig. 4) did not produce mature miRNA (0 out of 6). These results
suggest that our approach can be used to predict which candidate
Table 2. A list of 30 high frequency novel candidate miRNAs in breast cancer cells.
NAME SEQUENCE length MCF10A MCF7 MDA MIRBASE STAR LOCATION
hsa-miR-B1 GGCTGGTCCGAAGGTAGTGAGTTATCT 27 585 1347 1251 Novel No chr11:13304324–13304433[2]
hsa-miR-B2 CCTGCAGTAGCTGTTTCT 18 1 0 1651 Novel No chr9:73809165–73809274[2]
hsa-miR-B3 GGCTGGTCCGAGTGCAGTGGTGTTTACAACT 31 257 433 1007 Novel No chr13:98986564–98986673[2]
hsa-miR-B4 TAAAAGTAATTGTGGTATTTGC 22 0 0 57 1 mismatches
with hsa-548d-5p
No chr1: 81947441–81947550[+]
hsa-miR-B5 GAGCCCGGAGGGCGAGG 17 639 8 396 Novel No chr1:1172913–1173022[2]
hsa-miR-B6 AAGGTAGATAGAACAGGTCTTG 22 364 528 215 perfect match with
mouse, dog, cow
Yes(22) chr15:81221792–81221898[+]
hsa-miR-B7 CTGAGCAACATAGCGAGACCCCGTCTCTA 29 468 214 340 close to hsa-miR-
1303 (chr5) in
diff loc
No chr16:3297692–3297801[2]
hsa-miR-B8 AAGCCATGTTACGAGCCTTAAGG 23 20 28 15 Novel Yes(14) chr6:133180097–133180198[+]
hsa-miR-B9 TGTGGTCTAGTGGTTAGGAT 20 169 111 157 close to cow
(bta-mir-2476)
No chrY:586300–586319[+]
hsa-miR-B10 GGGGGTGTAGCTCAGTGGTAGAGCA 25 209 46 92 1 mismatch with
mmu-miR-1959
No chr6:28834104–28834213[2]
hsa-miR-B11 GGCCAGCCACCAGGAGGGCTGC 22 1 15 14 Novel Yes(5) chr20:49502834–49502934[2]
hsa-miR-B12 TGTTGGTGTTTATGTTG 17 0 0 78 Novel No chr8:107080026–107080135[+]
hsa-miR-B13 CCGTGTTTCCCCCACGCTTT 20 49 29 206 Novel No chr17:8031210–8031319[+]
hsa-miR-B14 GTCTCCTTGTTATGGGGCAGTGCAG 25 153 10 29 Novel No chr1:153915582–153915691[2]
hsa-miR-B15 AAAGACATAGTTGCAAGATGGG 22 0 0 80 Novel No chr20:43767137–43767246[2]
hsa-miR-B16 GTGGGTGATGTTTGCTGACA 20 32 2 28 Novel No chr22:40334774–40334883[2]
hsa-miR-B17 GGGCTGTGATGTTTATTAGCTTCTGAGCTC 30 180 16 36 Novel No chr17:38359009–38359118[2]
hsa-miR-B18 GATGGTGATGATGCTGGTC 19 0 0 26 Novel chr7: 91108780–91108889[+]
hsa-miR-B19 AAAAGGGGGCTGAGGTGGAG 20 8 0 133 Novel No chr11:121527997–
121528099[2]
hsa-miR-B20 CCAAGGAAGGCAGCAGG 17 19 22 125 Novel No chr1:202811178–202811287[2]
hsa-miR-B21 TATGTGTGTGTGCTTGTATAT 21 1 0 88 close to mouse
(mmu-miR-669)
No chr8:129122276–129122385[+]
hsa-miR-B22 TCCCCAGCACCTCCACCA 18 114 1 11 Novel No chr7:73108306–73108415[2]
hsa-miR-B23 TGAGGAATATGGTGATC 17 0 0 48 Novel No chr1:33878065–33878174[+]
hsa-miR-B24 GTTCTTGTAGTTGAAATACAACGATG 26 29 12 51 Novel No chr5:105917028–105917137[+]
hsa-miR-B25 TTGGCCATGGGGCTGCGCGG 20 33 42 36 Novel No chr19:764562–764671[+]
hsa-miR-B26 ATCCCACCACTGCCACCA 18 59 21 3 one mismatch
with hsa-miR-1260
No chr11:95714237–95714346[+]
hsa-miR-B27 CCAGGAATCCTGCTGTGGTGGA 22 8 0 50 Novel Yes(3) chr11:121532093–
121532199[2]
hsa-miR-B28 TGTCCTTGCTGTTTGGAGATAA 22 68 21 8 close to cow
(bta-mir-2355)
Yes(14) chr2:207682944–207683054[2]
hsa-miR-B29 ATGTGGGCTAGTTTCAGACAGGT 23 7 11 42 Novel No chr1:28778841–28778945[2]
hsa-miR-B30 CACCTTGCGCTACTCAGGTCTGC 23 13 47 15 Novel No chr22:29457597–29457619[+]
Candidate miRNAs in bold were used to evaluate miRNA expression using Northern blotting.
doi:10.1371/journal.pone.0016403.t002
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miRNA would qualify as bona fide miRNAs from miRNA deep
sequencing with about 90% accuracy. Although northern blot
analysis provides a direct evidence to determine precursor and
mature form of miRNA, there is a possiblity that the sensitivity of
notthern blotting may not be sufficient enough to detect lowly
expressed miRNAs. Therefore, we selected three miRNAs each
from two groups, designed custom Taqman miRNA probes
(Applied Biosystems) and performed miRNA QPCR assay. As
expected, consistent with the northern blot data, three candidate
miRNAs from Group B, miR-B4, miR-B15, miR-B28 were
detected, but none of three candidate miRNAs from Group A
were detected byQPCR assay (Fig. 4B and C). Notably, comparison
of validated candidate novel miRNAs and their stem lengths
between group A and B by Mann-Whitney statistical test showed
that two groups are significantly different (p,0.01) (Fig. 4D).
Given that the folding free energy analysis of pre-miRNA
secondary has proven insufficient to discriminate miRNA precur-
sors from other structures, additional criteria have been considered,
including preference for a 59 Uracil [31], stem or bulge symmetry
[31][32] , and frequencies of 3-nt elements combining base- pairing
and sequence characters [33], lower number and reduced size of
bulges and internal loops [30]. Although these parameters have
improved miRNA prediction, this prediction has not been tested in
experimental settings. In this study, we have demonstrated that
analysis of stem lengths generated by 500-nt pri-miRNA secondary
structure can be used to identify bona fide novel miRNAs from deep
Figure 2. Validation of candidate miRNAs by northern blot analysis and secondary structure prediction of precursor sequences. (A)
20mg of RNA (enriched for small RNA fraction) was isolated from MDA-MB-231 cells and fractionated on a 7% polyacrylamide gel and hybridized to
anti-sense oligo probes corresponding to miRNAs indicated above to detect processed 70-nt precursor and a 22-nt mature miRNA. In some cases,
500nt- precursors were cloned in lentiviral vectors to generate 293T cells stably expressing precursor miRNAs. RNA harvested from the transfected
cells was used for northern blot analysis. A highly abundant known miRNA, hsa-miR-21 was used as a control. Decade marker was used as a size
marker for small RNAs. (B) Secondary structures were predicted by RNA fold program using either a ,75-nt precursor sequence or the 500-nt
precursor sequence. The stem and loop structure of pre-miRNA are boxed. The location of mature miRNA sequence is denoted in red.
doi:10.1371/journal.pone.0016403.g002
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sequencing data. Perhaps experimental evaluation of a larger
number of candidate miRNAs will be necessary to accurately
determine the robustness of this method in the future.
Materials and Methods
Cell lines and expression of miRNA
Human breast cell lines MCF10A (nontumorigenic), MCF7
(tumorigenic, nonmetastatic) and MDA-MB-231 (tumorigenic,
metastatic) were obtained from ATCC. MCF10A cells were grown
in DMEM/F12 (Mediatech) with EGF (Peprotech), Hydrocorti-
zone (Sigma), Cholera Toxin (Sigma) and Insulin (Sigma) as
instructed in ATCC guideline. MCF7 and MDA-MB-231 cells
were grown in DMEM (Mediatech) with 10% FBS (Hyclone), 5%
glutamine (Mediatech), and 5% antibiotics-antimycotic solution
(Mediatech). To express miRNA in cells, ,500bp of pri-miRNA
were amplified and cloned into pZEO lentiviral construct in fusion
with a GFP reporter (gift from Patrick Paddison, Cold Spring
Figure 3. Distribution of the length of stem in known and unknown miRNA sequence reads. The pri-miRNA secondary structures in both
known miRNAs and candidate miRNAs were predicted by RNAfold program. The secondary structures of pre-miRNA were located and extracted to
measure the length of stem in both known miRNAs (A) and candidate miRNAs (B). Blue and red bars represent the distribution of longer stem length
(cutoff .30) and short stem length, respectively. Read frequencies with stem length of .30 or ,30 are indicated.
doi:10.1371/journal.pone.0016403.g003
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Harbor Lab). Lentivirus was generated by co-transfection of
pZEO constructs with packaging constructs pMD2G and psPAX2
into 293T cells as described [34]. Culture medium containing
lentivirus was collected at 48 and 72 h after transfection. The titer
of lentivirus was determined by infecting 293T cells and evaluating
% GFP+ cells. Cells were infected with pzeo-empty or with pzeo-
pri-miRNA at multiplicity of infection (MOI) of ,10. GFP signal
was used to sort cells stably expressing precursor miRNA by flow
cytometry.
Total RNA extraction, library construction and high-
throughput sequencing
Total RNA was extracted from breast cancer cells using
TRIZOL as per the manufacturer’s instructions (Invitrogen).
Approximately, 20mg of total RNA was fractionated through a
15% polyacrylamide-Urea gel (Sequagel, National diagnostic)
along with 32-P labeled 19–24bp oligonucleotide-delimiting
markers. Small RNA fraction was extracted from the gel slice
corresponding to the delimiting markers and used for generating
libraries for deep sequencing. Briefly, small RNAs were ligated
with Modban (Linker 1 from IDT). Ligated samples were
separated again on 15% Acrylamide/Urea gel. The gel fragments
corresponding to ,36–41 nt were excised. Small RNA was
purified from the gel fragments, and 59 sequencing linker was
added using T4 RNA ligase and ligated product (,68–73 nt)
separated on a 15% Polycrylamide/Urea gel. This RNA was
amplified using Superscript III Reverse transcriptase (Invitrogen)
and PCR amplification (Taq polymerase, Roche). Amplified
cDNA were separated on 2% Low melt agarose gel (SeaKem)
and the integrity of the small RNA libraries tested on 2100 Agilent
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Each library
was sequenced using Solexa 16genome sequencer (Illumina, San
Diego, CA).
Data Analysis
Sequencing images from Solexa 16 genome sequencer were
analyzed using the Illumina Pipeline v1.3.2 software to remove
background noise and to extract the first 36 bases of the runs.
Sequence reads were aligned to the hg18 genome (UCSC genome
browser) using the Eland software (Illumina, San Diego, CA). Next
the linker sequences were identified and trimmed from individual
reads using a customized Perl script. Reads in which the linker
sequences were either mutated or absent were discarded. Next, the
high confidence trimmed reads were aligned to known miRNAs
available in the miRBase (v16, www.mirbase.org), to obtain
sequences that either matched or did not match to known
miRNAs and their frequencies calculated. Unmatched sequences
were collapsed to obtain a set of unique reads. The reads that
passed were analyzed by miRDeep algorithm to predict novel
miRNAs [18,19]. Briefly, reads were mapped to human genome
(human genome v18, UCSC genome browser) using Megablast
[27] to identify reads with perfect matches. Reads that aligned to
more than five positions in the genome were removed from the
dataset, as these may comprise of repetitive sequences. The
remaining reads were subjected to noncoding RNA database
(NONCODE, v2.0, http://www.noncode.org) to remove the
contamination of human noncoding RNA such as snRNA,
snoRNA, r-RNA, t-RNA [35]. From the rest potential precursors
(,75bp) were excised to generate secondary stem-loop structure
using Vienna RNAfold package v1.8 (http://rna.tbi.univie.ac.at/)
[28]. Finally, miRDeep assigned a score to each read based on: (a)
seed sequence homology to known human miRNA, (b) presence of
a star sequence, (c) minimum free energy (RNAfold), (d) energetic
stability (Randfold), (e) frequency of reads that correspond to Dicer
processing. A final score was assigned and the minimum total score
by default was 1.
To measure the length of stem in the secondary structure of
miRNAs, ,500-nt precursor sequences were extracted and
secondary structure generated using Vienna RNAfold package.
The stem length was measured by counting the nucleotides
between hairpin loop junction and the base of the stem/bulge
defined as more than four consecutive non-paring nucleotides or
starting point of other stem branches.
Northern blotting
Small RNAs were enriched using mirVana small RNA
extraction kit as per the manufacturer’s manual (Ambion, Applied
Biosystems, CA). 20 mg of enriched RNA was fractionated through
a 7% polyacrylamide gel with decade RNA makers (Ambion,
Applied Biosystems) for an hour and transferred into Hybond-N+
positively charged nylon transfer membrane (Amersham) using
semidry membrane transfer apparatus (Biorad) for 45min at
100mA. Following transfer, RNA was fixed to the membrane
using a UV-crosslinker. Oligo probes obtained from Sigma were
labeled using gamma-32P ATP (.3000 Ci/mmol) and T4
polynucleotide kinase (10U/ul, NEB) for an hour at 37uC.
Unincorporated isotope was removed using a quick spin column
(Roche) as per the manufacturer’s instructions. Membranes were
hybridized with labeled probes using Ultrahyb-Oligo solution
(Ambion, Applied Biosystems) overnight at 42uC. After hybrid-
ization, membranes were washed twice in 2X SSC (Ambion,
Applied Biosystems) and exposed to film.
Taqman miRNA QPCR
Taqman probes for miR-B1, miR-B4, miR-B7, miR-B9, miR-
15 and miR-28 were designed using Custom TaqMan Small RNA
Assays (Applied Biosystems, CA). Human small nucleolar RNA,
RNU48 was used as endogenous controls (Applied Biosystems).
10ng of RNA were used to make cDNA using Taqman microRNA
assays kit and QPCR was performed as per the manufacturer’s
manual (Applied Biosystems, CA).
Supporting Information
Figure S1 Pre- and pri-miRNA sequence of hsa-miR-21
and its secondary structure. (A) The sequence in bold
represents 75-nt pre-miRNA and mature miRNA sequences
Figure 4. Northern blot and Taqman QPCR analysis showing that novel candidate miRNAs with stem lengths of $30bp may
comprise bona fidemiRNAs. (A) The expression of miRNA was examined by northern blotting using end-labeled oligonucleotide probes. A total of
10 candidate miRNAs were selected from Table 2 and their 500-nt precursors cloned in plasmids and overexpressed in 293T cells to detect processed
70-nt pre-miRNA and a mature miRNA. The numbers in parentheses represent the read frequency in MDA-MB-231 cells obtained from deep
sequencing. The numbers at the bottom indicate the length of stem in individual candidate miRNAs. A synthetic 32P-labeled RNA marker was used as
a size marker. Asterisk indicate miRNAs selected for QPCR validation. Taqman miRNA assay showed expression of candidate miRNAs from each group
by Ct values (B) and fold change (C). RNU48 was used as positive control and no-template control (NTC) used as negative control. (D) Box plot graph
showing correlation between validated miRNA and non-validated miRNA with their stem length. Mann-Whitney test showing that the two groups are
statistically different (p,0.001).
doi:10.1371/journal.pone.0016403.g004
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depicted in red. (B) A predicted stem-loop secondary structure of
75-nt pre-miR-21. Sequences corresponding to the mature
miRNAs are shown in red. (C) A predicted stem-loop secondary
structure derived from a 500-nt pri-miR-21. The length of the
stem is measured by counting nucleotides from the stem-loop
junction to the end of stem.
(TIF)
Figure S2 Comparison of the secondary structures of
75-nt pre-miRNA and 500-nt pri-miRNA for highly
expressed 30 candidate miRNAs. Nucleotide sequences
represent the primary sequence of precursor miRNA. Parentheses,
‘‘(’’ and ‘‘)’’ indicate the base pairing. Dots represent unpaired
nucleotide. miRNAs in blue were validated by northern blotting.
‘‘Pass’’ and ‘‘Fail’’ indicate pass or fail to form loop-stem structure,
respectively.
(DOC)
Table S1 Statistical values in each step of the pipeline to find
candidate miRNAs in various breast cancer cells.
(DOC)
Table S2 A list of candidate miRNAs predicted by mirDeep
algorithm.
(DOC)
Table S3 A lists of miRNA evaluated by Northern blot.
(DOC)
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